IL180675A0 - Methods of treating ccr2 mediated diseases or disorsers - Google Patents

Methods of treating ccr2 mediated diseases or disorsers

Info

Publication number
IL180675A0
IL180675A0 IL180675A IL18067507A IL180675A0 IL 180675 A0 IL180675 A0 IL 180675A0 IL 180675 A IL180675 A IL 180675A IL 18067507 A IL18067507 A IL 18067507A IL 180675 A0 IL180675 A0 IL 180675A0
Authority
IL
Israel
Prior art keywords
disorsers
methods
mediated diseases
ccr2 mediated
treating
Prior art date
Application number
IL180675A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL180675A0 publication Critical patent/IL180675A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL180675A 2004-07-30 2007-01-11 Methods of treating ccr2 mediated diseases or disorsers IL180675A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59268304P 2004-07-30 2004-07-30
PCT/IB2005/002162 WO2006013427A2 (en) 2004-07-30 2005-07-18 Treatment of ccr2 mediated diseases or disorders

Publications (1)

Publication Number Publication Date
IL180675A0 true IL180675A0 (en) 2007-06-03

Family

ID=35207829

Family Applications (1)

Application Number Title Priority Date Filing Date
IL180675A IL180675A0 (en) 2004-07-30 2007-01-11 Methods of treating ccr2 mediated diseases or disorsers

Country Status (14)

Country Link
US (1) US20090196823A1 (enExample)
EP (1) EP1778285A2 (enExample)
JP (1) JP2008508253A (enExample)
KR (1) KR20080044360A (enExample)
CN (1) CN101005855A (enExample)
AU (1) AU2005268545A1 (enExample)
BR (1) BRPI0513953A (enExample)
CA (1) CA2575612A1 (enExample)
IL (1) IL180675A0 (enExample)
MX (1) MX2007001204A (enExample)
NO (1) NO20070996L (enExample)
RU (1) RU2007103332A (enExample)
WO (1) WO2006013427A2 (enExample)
ZA (1) ZA200700823B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629351B2 (en) 2006-07-28 2009-12-08 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process
US7671062B2 (en) 2006-07-28 2010-03-02 Bristol-Myers Squibb Company Modulators of chemokine receptor activity, crystalline forms and process
US7687508B2 (en) 2006-07-28 2010-03-30 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
PE20110774A1 (es) 2008-08-18 2011-10-13 Amgen Fremont Inc Anticuerpos para ccr2
US8383812B2 (en) 2009-10-13 2013-02-26 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
US9726666B2 (en) 2011-06-13 2017-08-08 Tla Targeted Immunotherapies Ab Diagnosing and treating inflammatory diseases
DK2723360T3 (en) * 2011-06-27 2017-08-28 Univ Pierre Et Marie Curie Paris 6 CCR2 antagonist peptides
WO2022235440A1 (en) * 2021-04-21 2022-11-10 The United States Government As Represented By The Department Of Veterans Affairs Method for treating traumatic brain injury, spinal cord injury, or stroke using small molecule inhibitors of ccr2

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312689B1 (en) * 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
FR2792837B1 (fr) * 1999-04-29 2001-07-13 Centre Nat Rech Scient Medicaments utiles pour le traitement des troubles de la regulation de la masse adipeuse et des maladies associees aux troubles de la production de leptine
US20050245537A1 (en) * 2002-04-24 2005-11-03 Noboru Tsuchimori Use of compounds having ccr antagonism
JP2007523871A (ja) * 2003-07-15 2007-08-23 メルク　エンド　カムパニー　インコーポレーテッド ケモカイン受容体活性の７および８員複素環式シクロペンチルベンジルアミドモジュレーター
MXPA06007000A (es) * 2003-12-18 2006-08-31 Incyte Corp Derivados de 3-cicloalquilaminopirrolidina como moduladores de receptores de quimiocina.

Also Published As

Publication number Publication date
WO2006013427A2 (en) 2006-02-09
WO2006013427A3 (en) 2006-06-08
CA2575612A1 (en) 2006-02-09
RU2007103332A (ru) 2008-08-10
KR20080044360A (ko) 2008-05-20
MX2007001204A (es) 2007-03-23
US20090196823A1 (en) 2009-08-06
AU2005268545A1 (en) 2006-02-09
NO20070996L (no) 2007-04-23
ZA200700823B (en) 2008-10-29
CN101005855A (zh) 2007-07-25
EP1778285A2 (en) 2007-05-02
JP2008508253A (ja) 2008-03-21
BRPI0513953A (pt) 2008-05-20

Similar Documents

Publication Publication Date Title
IL189528A0 (en) Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases
IL172346A0 (en) Treatment of t cell mediated diseases by inhibition of fgfr3
IL171961A0 (en) Treatment of t-cell mediated diseases
IL174698A0 (en) Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases
HRP20150175T1 (en) Means and methods for the treatment of tumorous diseases
IL227841A0 (en) Dihydropyridinones for the treatment of cancer
EP1737482A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES
PL2302097T3 (pl) Metoda obróbki powierzchni
IL169602A0 (en) Methods of treating lung diseases
IL183781A0 (en) Pyridine compounds for the treatment of prostaglandin mediated diseases
IL182436A0 (en) Thienopyridinone compounds and methods of treatment
IL180675A0 (en) Methods of treating ccr2 mediated diseases or disorsers
IL178996A0 (en) Thienopyridinone compounds and methods of treatment
EP1789047A4 (en) PROCESS FOR TREATING DISEASES USING NALMEFENE AND ITS ANALOGUES
ZA200806095B (en) Means and methods for the treatment of tumorous diseases
EP1768678A4 (en) METHODS FOR SELECTIVE TREATMENT OF DISEASES BY SPECIFIC GLYCOSAMINOGLYCAN POLYMERS
GB0422634D0 (en) Method of treating skin diseases
EP1740221A4 (en) METHOD AND COMPOSITIONS FOR TREATING POLYCYSTIC DISEASES
GB0426196D0 (en) Methods of treatment
EP1781318A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF POLYKYSTIC DISEASES
GB0526394D0 (en) Treatment of inflammatory diseases
EP1718329A4 (en) METHOD FOR THE TREATMENT OF SKIN DISEASES
AP2007004017A0 (en) Pyridine compounds for the treatment of prostaglandin mediated diseases
GB0425054D0 (en) Formamide derivatives for the treatment of diseases
GB0407710D0 (en) Treatment of diseases